Role of mutagenicity in asbestos fiberinduced carcinogenicity and other diseases, J Toxicol Environ Health B Crit Rev, vol.14, pp.179-245, 2011. ,
Guidelines of the European Respiratory Society and the European Society of Thoracic Surgeons for the management of malignant pleural mesothelioma, Eur Respir J, vol.35, pp.479-95, 2010. ,
Cytogenetic and molecular genetic changes in malignant mesothelioma, Cancer Genet Cytogenet, vol.170, pp.9-15, 2006. ,
Gene copy number analysis in malignant pleural mesothelioma using oligonucleotide array CGH, Cytogenet Genome Res, vol.119, pp.46-52, 2007. ,
Genomic profiling of malignant pleural mesothelioma with array-based comparative genomic hybridization shows frequent non-random chromosomal alteration regions including JUN amplification on 1p32, Cancer Sci, vol.98, pp.438-484, 2007. ,
Molecular changes in mesothelioma with an impact on prognosis and treatment, Arch Pathol Lab Med, vol.136, pp.277-93, 2012. ,
URL : https://hal.archives-ouvertes.fr/inserm-02478588
Syntenic Relationships between Genomic Profiles of Fiber-Induced Murine and Human Malignant Mesothelioma, Am J Pathol, vol.178, pp.881-94, 2011. ,
URL : https://hal.archives-ouvertes.fr/inserm-00531343
doubleblind, placebo-controlled, randomized phase II trial of gemcitabine/cisplatin plus bevacizumab or placebo in patients with malignant mesothelioma, J Clin Oncol, vol.30, pp.2509-2524, 2012. ,
Chemotherapy of malignant pleural mesothelioma, Expert Opin Pharmacother, vol.10, pp.99-107, 2009. ,
Immunohistochemistry and molecular diagnostics of pleural malignant mesothelioma, Arch Pathol Lab Med, vol.136, pp.253-61, 2012. ,
Guidelines for Pathologic Diagnosis of Malignant Mesothelioma: 2012 Update of the Consensus Statement from the International Mesothelioma Interest Group, Arch Pathol Lab Med, vol.137, pp.647-67, 2012. ,
Epigenetic profiles distinguish malignant pleural mesothelioma from lung adenocarcinoma, Cancer Res, vol.69, pp.9073-82, 2009. ,
Epigenetic profiles distinguish pleural mesothelioma from normal pleura and predict lung asbestos burden and clinical outcome, Cancer Res, vol.69, pp.227-261, 2009. ,
Identification of novel candidate oncogenes and tumor suppressors in malignant pleural mesothelioma using largescale transcriptional profiling, Am J Pathol, vol.166, pp.1827-1867, 2005. ,
CDKN2A, NF2, and JUN are dysregulated among other genes by miRNAs in malignant mesothelioma -A miRNA microarray analysis, Genes Chromosomes Cancer, vol.48, pp.615-638, 2009. ,
microRNA-1 Induces Growth Arrest and Apoptosis in Malignant Mesothelioma, Chest, 2013. ,
Guidelines for pathologic diagnosis of malignant mesothelioma: a consensus statement from the International Mesothelioma Interest Group, Arch Pathol Lab Med, vol.133, pp.1317-1348, 2009. ,
Immunocytochemical characterization of cell lines from human malignant mesothelioma: characterization of human mesothelioma cell lines by immunocytochemistry with a panel of monoclonal antibodies, Hum Pathol, vol.25, pp.227-261, 1994. ,
In vitro effects of recombinant human interferon gamma on human mesothelioma cell lines, Int J Cancer, vol.55, pp.515-535, 1993. ,
The nuclear deubiquitinase BAP1 is commonly inactivated by somatic mutations and 3p21.1 losses in malignant pleural mesothelioma, Nat Genet, vol.43, pp.668-72, 2011. ,
p16INK4A inactivation mechanisms in non-small-cell lung cancer patients occupationally exposed to asbestos, Lung Cancer, vol.67, pp.23-30, 2010. ,
URL : https://hal.archives-ouvertes.fr/inserm-00388198
Differential mutation profiles and similar intronic TP53 polymorphisms in asbestos-related lung cancer and pleural mesothelioma, Mutagenesis, vol.28, pp.323-354, 2013. ,
URL : https://hal.archives-ouvertes.fr/inserm-02478590
Summaries of Affymetrix GeneChip probe level data, Nucleic Acids Res, vol.31, p.15, 2003. ,
Hepatic stem-like phenotype and interplay of Wnt/beta-catenin and Myc signaling in aggressive childhood liver cancer, Cancer Cell, vol.14, pp.471-84, 2008. ,
Diagnosis of multiple cancer types by shrunken centroids of gene expression, Proc Natl Acad Sci U S A, vol.99, pp.6567-72, 2002. ,
Empirical bayes methods and false discovery rates for microarrays, Genet Epidemiol, vol.23, pp.70-86, 2002. ,
A global test for groups of genes: testing association with a clinical outcome, Bioinformatics, vol.20, pp.93-102, 2004. ,
Improving gene set analysis of microarray data by SAM-GS, BMC Bioinformatics, vol.8, p.242, 2007. ,
Analyzing gene expression data in terms of gene sets: methodological issues, Bioinformatics, vol.23, pp.980-987, 2007. ,
Plasma cell membrane localization of c-MET predicts longer survival in patients with malignant mesothelioma: a series of 157 cases from the MESOPATH Group, J Thorac Oncol, vol.7, pp.599-606, 2012. ,
URL : https://hal.archives-ouvertes.fr/hal-01853402
TGF-beta and epithelial-to-mesenchymal transitions, Oncogene, vol.24, pp.5764-74, 2005. ,
Complex networks orchestrate epithelial-mesenchymal transitions, Nat Rev Mol Cell Biol, vol.7, pp.131-173, 2006. ,
Biomarkers for epithelial-mesenchymal transitions, J Clin Invest, vol.119, pp.1429-1466, 2009. ,
Core epithelial-tomesenchymal transition interactome gene-expression signature is associated with claudin-low and metaplastic breast cancer subtypes, Proc Natl Acad Sci U S A, vol.107, pp.15449-54, 2010. ,
Treatment of malignant pleural mesothelioma: current status and future directions, Monaldi Arch Chest Dis, vol.73, pp.79-85, 2010. ,
Targeted therapies in malignant pleural mesothelioma: a review of clinical studies, Anticancer Drugs, vol.22, pp.199-205, 2011. ,
Review on clinical trials of targeted treatments in malignant mesothelioma, Cancer Chemother Pharmacol, vol.68, pp.1-15, 2011. ,
URL : https://hal.archives-ouvertes.fr/hal-00694874
Gene expression profiling identifies matriptase overexpression in malignant mesothelioma, Chest, vol.125, pp.1843-52, 2004. ,
Identification of novel markers for the diagnosis of malignant pleural mesothelioma, Am J Pathol, vol.178, pp.1033-1075, 2011. ,
Global gene expression profiling of pleural mesotheliomas: overexpression of aurora kinases and P16/CDKN2A deletion as prognostic factors and critical evaluation of microarray-based prognostic prediction, Cancer Res, vol.66, pp.2970-2979, 2006. ,
LRRN4 and UPK3B are markers of primary mesothelial cells, PLoS One, vol.6, p.25391, 2011. ,
Regulation of fibrin deposition by malignant mesothelioma, Am J Pathol, vol.147, pp.1318-1347, 1995. ,
Pathogenesis of pleural fibrosis, Respirology, vol.9, pp.428-468, 2004. ,
Gene expression profiles predict survival and progression of pleural mesothelioma, Clin Cancer Res, vol.10, pp.849-59, 2004. ,
Using gene expression ratios to predict outcome among patients with mesothelioma, J Natl Cancer Inst, vol.95, pp.598-605, 2003. ,
Validation of genomics-based prognostic tests in malignant pleural mesothelioma, Clin Cancer Res, vol.11, pp.4406-4420, 2005. ,
Four-gene expression ratio test for survival in patients undergoing surgery for mesothelioma, J Natl Cancer Inst, vol.101, pp.678-86, 2009. ,
Germline BAP1 mutations predispose to malignant mesothelioma, Nat Genet, vol.43, pp.1022-1027, 2011. ,
Effects on survival of BAP1 and PBRM1 mutations in sporadic clear-cell renal-cell carcinoma: a retrospective analysis with independent validation, Lancet Oncol, vol.14, pp.159-67, 2013. ,
Frequent mutation of BAP1 in metastasizing uveal melanomas, Science, vol.330, pp.1410-1413, 2010. ,
Clinical Characteristics of Patients with Malignant Pleural Mesothelioma Harboring Somatic BAP1 Mutations, J Thorac Oncol, vol.8, pp.1430-1433, 2013. ,
Immunohistochemistry in the distinction between malignant mesothelioma and pulmonary adenocarcinoma: a critical evaluation of new antibodies, J Clin Pathol, vol.55, pp.662-670, 2002. ,
Epithelialmesenchymal transition in malignant mesothelioma, Mod Pathol, vol.25, pp.86-99, 2012. ,
Expression of snail, twist, and Zeb1 in malignant mesothelioma, APMIS, vol.121, pp.1-10, 2013. ,
Prognostic significance of epithelial-mesenchymal transition in malignant pleural mesothelioma, Eur J Cardiothorac Surg, vol.37, pp.566-72, 2010. ,
Deconstructing the mechanisms and consequences of TGFbeta-induced EMT during cancer progression, Cell Tissue Res, vol.347, pp.85-101, 2012. ,
Targeting the TGFbeta signalling pathway in disease, Nat Rev Drug Discov, vol.11, pp.790-811, 2012. ,
Regulation of epithelial-mesenchymal and mesenchymal-epithelial transitions by microRNAs, Curr Opin Cell Biol, vol.25, pp.200-207, 2013. ,
, The expression of EMT positive markers (POSTN, VCAN, SNAI2, TCF4, HMGA2) and negative markers (CDH1, CDH3) was measured by qRT-PCR, and differential expression of these markers between C1 and C2 samples was tested using Mann-Whitney tests in MPM in culture (upper panel) and in MPM tumor samples (lower panel). For each tested marker, box plots of -??Ct normalized values are shown for C1 (blue) and C2 (red), respectively. MPM and p-values are indicated above. Data showed up-regulation of EMT positive marker expression and down-regulation of negative marker, gives the log2 ratio of expression between C2 and C1 samples. (B)
, A-B) Cell extracts prepared from 25 different epithelioid MPM in culture were submitted to SDS-PAGE and analyzed by Western blot using anti-E-cadherin antibody. GAPDH expression was also analyzed in controls. Representative Western blots are shown (A). E-cadherin is detected as a protein of 120 kDa in all of the C1 MPM. Each band corresponding to E-cadherin and GAPDH was quantified, expressed using arbitrary units and normalized to the expression of MESO_07 cells. The ratio Ecadherin/GAPDH is shown on the graph for each MPM subgroup (B). E-cadherin expression at the protein level is higher in C1 than in C2 MPM in culture. (C-F) E-cadherin immunostaining of paraffinembedded tumors in representative cases of epithelioid (C,D) and biphasic (E,F) MPM is shown, MPM molecular subgroups